The IASLC 2026 World Conference on Lung Cancer opens in Seoul with a program that captures how profoundly thoracic oncology is changing. Across non–small cell and small cell lung cancer, the dominant question is no longer simply whether new therapies are active. Increasingly, investigators are asking when the most effective treatment should be introduced, how molecularly selected therapy should be integrated around surgery, and whether newer immune and targeted modalities can replace standards that have persisted for decades.
WCLC 2026 is being held September 12–15 and brings together more than 5,700 international delegates, with 1,677 abstracts spanning prevention, screening, surgery, radiation oncology, immunotherapy, targeted therapy, and translational science. The meeting’s presidential program prominently features MAVERICK, TAISHAN-302, ARTEMIS-008, EVOKE-03, ADAURA, PAPILLON, REZILIENT3, ARROS-1, and DESTINY-Lung04.
Because several of the most important late-breaking datasets remain under conference embargo until presentation, the opening-day picture is necessarily a combination of publicly released abstracts, previously announced phase III topline results, and the major questions that the plenary presentations are expected to resolve. The scientific direction, however, is already clear: targeted therapy is moving earlier, perioperative treatment is becoming molecularly individualized, and SCLC is experiencing one of its most active periods of therapeutic development in years.
Small Cell Lung Cancer Moves Beyond Checkpoint Inhibition
Perhaps the most striking feature of WCLC 2026 is the strength of the small cell lung cancer program.
For several years, progress in extensive-stage SCLC was dominated by the addition of PD-L1 inhibition to platinum–etoposide. That established a new first-line standard but produced relatively modest gains in a disease still characterized by rapid relapse and high postprogression attrition.
The next therapeutic wave is substantially different. DLL3-directed T-cell engagers and B7-H3-directed antibody–drug conjugates are now being tested in settings where topotecan, conventional chemotherapy, or maintenance immunotherapy have historically dominated.
The importance of this transition was reinforced immediately before WCLC by positive topline results from the phase III DeLLphi-305 trial. Patients with ES-SCLC who had not progressed after durvalumab plus platinum–etoposide induction were randomized to maintenance durvalumab plus tarlatamab or durvalumab alone. The combination significantly improved the primary endpoint of overall survival and also improved PFS and objective response rate, with no new safety signals reported. Numerical survival results remain undisclosed.
Although the full magnitude of that survival improvement still needs to be seen, the strategic message is important. Tarlatamab is no longer being conceptualized only as a treatment to rescue patients after relapse. The field is testing whether DLL3-directed immune engagement should begin before progression, while disease remains controlled after induction therapy.
That approach directly addresses one of the central problems in SCLC: some patients deteriorate so rapidly after relapse that they never reach an effective subsequent line of treatment.
DLL3 Is Becoming a Therapeutic Backbone Rather Than a Late-Line Target
Tarlatamab engages DLL3 on SCLC cells and CD3 on T cells, redirecting cytotoxic T-cell activity toward the tumor. DLL3 is expressed on the surface of approximately 85%–96% of SCLC tumors while being minimally expressed on healthy cells, providing a biologically attractive target in a disease that lacks the abundance of actionable genomic drivers seen in NSCLC.
WCLC will also feature DeLLphi-309, evaluating extended-interval tarlatamab dosing. This may appear less dramatic than an OS-positive phase III trial, but implementation matters. T-cell engagers can create logistical challenges through monitoring requirements and early-treatment toxicity management. A more convenient dosing strategy could influence how broadly DLL3-directed therapy can move into routine practice.
The clinical development of tarlatamab therefore illustrates an increasingly important theme in oncology: once efficacy is established, the next phase of innovation involves moving treatment earlier and making delivery more practical.
B7-H3 ADCs Challenge Topotecan in Relapsed SCLC
The second major SCLC theme is B7-H3.
Two phase III trials in the Presidential Symposium directly compare B7-H3-directed ADCs with topotecan in relapsed SCLC: TAISHAN-302, evaluating tam-peli, and ARTEMIS-008, evaluating risvutatug rezetecan. Both are positioned to test whether ADC technology can replace one of the long-standing chemotherapy comparators in relapsed SCLC.
These studies matter beyond their individual drugs. SCLC has historically been treated largely according to stage and treatment-free interval rather than a therapeutically exploitable surface antigen. DLL3 and B7-H3 now suggest a different future in which SCLC can be approached through tumor-associated surface biology, even without classic oncogenic drivers.
If mature phase III evidence confirms clinically meaningful survival benefits, the post-platinum treatment landscape could evolve rapidly from conventional cytotoxic sequencing toward competing ADC and T-cell engager strategies.
The critical questions will be magnitude of OS benefit, duration of response, hematologic toxicity, interstitial lung disease where relevant, and how these therapies compare indirectly with the increasingly established role of tarlatamab.
MAVERICK Could Change What We Do Rather Than Add Another Drug
Not every potentially practice-changing WCLC study involves systemic therapy.
SWOG S1827 MAVERICK examines MRI surveillance with or without prophylactic cranial irradiation in SCLC patients without brain metastases on MRI after initial therapy. It addresses one of the most persistent controversies in contemporary SCLC management: whether PCI continues to provide sufficient benefit in an era of high-quality serial MRI surveillance.
The implications could be unusually direct. A definitive result may not introduce another treatment—it could potentially remove or substantially narrow an existing one.
That is particularly relevant because the balance between preventing brain metastases and avoiding neurocognitive toxicity has become increasingly important as imaging improves and systemic survival gradually lengthens.
Among all WCLC 2026 studies, MAVERICK may therefore have one of the clearest opportunities to alter everyday clinical decision-making.
EVOKE-03 Provides an Important Negative Lesson for ADC–Immunotherapy Combinations
Not every anticipated ADC strategy has succeeded. The phase III EVOKE-03/KEYNOTE-D46 study tested sacituzumab govitecan plus pembrolizumab against pembrolizumab alone in previously untreated metastatic NSCLC with PD-L1 TPS ≥50%.
Merck and Gilead announced in June that the study was discontinued following Data Monitoring Committee review. Although PFS numerically favored the ADC combination, the improvement did not reach statistical significance, and the probability of demonstrating a statistically significant OS benefit at the planned final analysis was considered unlikely.
The primary-results presentation at WCLC remains important because it may explain why adding a highly active ADC to checkpoint blockade failed to improve on first-line pembrolizumab.
The result provides a useful counterweight to enthusiasm surrounding ADC combinations. More therapy does not automatically produce better outcomes, even when both components have individual antitumor activity.
Patient selection, payload biology, tumor immune environment, toxicity, dose intensity, and sequencing may all matter more than simply combining mechanisms.
Targeted Therapy Is Moving Into the First Treatment Decision
If the SCLC program is defined by new therapeutic modalities, the oncogene-driven NSCLC program is defined by earlier intervention. The second Presidential Symposium brings together ADAURA, PAPILLON, REZILIENT3, ARROS-1, and DESTINY-Lung04, a remarkably concentrated group of trials asking how targeted therapy should be positioned across EGFR-, ROS1-, and HER2-driven disease.
The conceptual shift is increasingly familiar across precision oncology. Once a molecular therapy demonstrates strong activity in later-line disease, development rapidly moves toward first-line treatment and, increasingly, toward curative-intent early disease.
WCLC 2026 may accelerate that shift across several molecular subgroups simultaneously.
ADAURA Asks Whether the Benefit Persists Long After Treatment Stops
ADAURA has already established adjuvant osimertinib as a standard for appropriately selected patients with completely resected EGFR-mutated NSCLC.
The WCLC presentation is therefore not about establishing efficacy for the first time. It is an exploratory eight-year overall-survival landmark update, asking whether the benefit remains durable years after patients completed the prescribed three years of osimertinib. This is an increasingly important issue in curative-intent targeted therapy.
If survival curves remain clearly separated long after treatment discontinuation, it strengthens the interpretation that adjuvant therapy is preventing or substantially delaying clinically important recurrence rather than merely postponing events during drug exposure.
Long-term recurrence patterns, CNS events, postrecurrence therapy, and the shape of the OS curve may ultimately be more informative than another short-term landmark estimate.
EGFR Exon 20 Insertions Become a First-Line Sequencing Competition
EGFR exon 20 insertion–mutated NSCLC is emerging as one of the most competitive molecular spaces at WCLC. The final OS analysis of PAPILLON will update first-line amivantamab plus chemotherapy, while REZILIENT3 introduces the competing strategy of zipalertinib plus platinum-based chemotherapy.
REZILIENT3 has already announced that it met its primary endpoint. In 285 previously untreated patients with advanced nonsquamous EGFR exon 20 insertion–positive NSCLC, zipalertinib plus chemotherapy produced a statistically significant and clinically meaningful PFS improvement compared with chemotherapy alone at the planned interim analysis. Numerical PFS, response, OS, and detailed safety results had not been disclosed in the initial announcement.
The WCLC data will therefore be important not simply because another regimen is positive.
The emerging question is which therapeutic architecture should dominate first line: bispecific EGFR–MET blockade plus chemotherapy, a mutation-directed TKI plus chemotherapy, or eventually other targeted strategies.
That competition will increasingly depend on CNS efficacy, tolerability, depth of response, durability, convenience, and resistance biology rather than PFS alone.
HER2-Mutant NSCLC May Move Directly to Targeted First-Line Therapy
Few WCLC datasets have greater potential to alter molecular sequencing than DESTINY-Lung04. The phase III study compares trastuzumab deruxtecan with platinum–pemetrexed plus pembrolizumab as first-line therapy for unresectable locally advanced or metastatic HER2-mutant nonsquamous NSCLC.
AstraZeneca and Daiichi Sankyo announced in August that DESTINY-Lung04 met its primary endpoint, with T-DXd producing a statistically significant and clinically meaningful improvement in blinded-independent-review PFS. Overall survival remains under follow-up.
The importance of the study lies in its comparator. T-DXd is not being tested against an obsolete treatment, it is being tested against global first-line chemoimmunotherapy.
If the complete WCLC results demonstrate a compelling magnitude of benefit with a favorable benefit-risk profile, HER2-mutant NSCLC could move toward the same model already established for several other oncogenic drivers: identify the alteration before therapy and use molecularly matched treatment from the outset.
That discussion has become even more timely after the FDA’s September 9 accelerated approval of sevabertinib for previously untreated advanced nonsquamous NSCLC with HER2 TKD–activating mutations.
HER2-mutant NSCLC is rapidly becoming not only targetable, but a sequencing problem between distinct HER2-directed modalities.
ROS1 Therapy Continues to Prioritize CNS Control and Resistance Coverage
The ARROS-1 presentation will examine zidesamtinib in TKI-naïve ROS1-positive advanced NSCLC. Zidesamtinib received FDA approval in July 2026 for patients who had previously received at least one ROS1 TKI.
Earlier TKI-naïve data have already generated considerable interest. Publicly reported ARROS-1 results in a smaller first-line cohort showed an ORR of approximately 89%, with a high proportion of responses extending beyond 12 months.
The WCLC presentation will help determine whether zidesamtinib can realistically compete with established first-line ROS1 inhibitors.
As in ALK-positive disease, the differentiating characteristics of future ROS1 therapy are likely to be not merely initial response rate but CNS penetration, resistance-mutation coverage, duration of control, and long-term tolerability.
Precision Oncology Is Entering the Neoadjuvant Setting
One of the most important developments outside the plenary sessions is the movement of genotype-directed therapy into resectable NSCLC.
In the ALK-positive cohort of NAUTIKA1, 48 patients with resectable stage IB–IIIB disease received eight weeks of neoadjuvant alectinib before surgery. Publicly released WCLC abstract data show major pathologic response in 55.8%, pCR in 18.6%, radiographic response in 60%, and R0 resection in 95% of operated patients. At a median follow-up of 20.8 months, the reported two-year EFS, DFS, and OS estimates were 94%, 96%, and 97%, respectively.
The KRAS G12C cohort provides a parallel proof of concept.
Twenty patients received eight weeks of neoadjuvant divarasib. Public abstract data report MPR of 42%, pCR of 16%, and radiographic ORR of 55%. Nineteen patients underwent surgery and all achieved R0 resection, without reported surgical delays or intraoperative complications.
These are relatively small phase II datasets and should not be interpreted as establishing new standards. Their significance is conceptual. Molecular testing in early NSCLC is becoming relevant before surgery, not simply afterward when adjuvant treatment is being selected.
Stage III Disease Is Becoming Dynamically Reclassified During Treatment
The phase II MDT-BRIDGE study addresses another important clinical problem: the boundary between resectable and unresectable stage III NSCLC.
Patients with resectable or borderline-resectable stage IIB–IIIB disease received two cycles of neoadjuvant durvalumab plus chemotherapy followed by multidisciplinary reassessment. Depending on reassessed operability, patients proceeded toward surgery or definitive chemoradiotherapy, with subsequent durvalumab incorporated into the pathway.
Publicly released abstract data show a resection rate of 74.6%, with R0 resection in 96.2% of those undergoing surgery. Among patients categorized as resectable at reassessment, pCR was 27.3% and 12-month EFS was 90.1%; among those managed as unresectable, 12-month PFS was 75.1%.
The importance of MDT-BRIDGE is less about identifying a universal regimen than demonstrating a different model of stage III management.
Resectability need not always be treated as a permanent label determined at the first consultation. Neoadjuvant therapy followed by structured multidisciplinary reassessment can allow treatment pathways to adapt according to tumor response and technical operability. WCLC will also present the final analysis of the randomized phase III IMpower030 perioperative atezolizumab study, adding another major dataset to the increasingly crowded curative-intent immunotherapy landscape.
The Central WCLC 2026 Story Is Earlier, More Selective Treatment
Taken together, the most important WCLC 2026 studies point toward a common direction. In SCLC, active therapies are moving from salvage into maintenance, while DLL3 and B7-H3 are creating treatment strategies based on surface biology rather than conventional chemotherapy sensitivity.
In oncogene-driven NSCLC, targeted therapies are moving from later lines into first-line metastatic treatment and from metastatic disease into the perioperative setting. In stage III NSCLC, multidisciplinary reassessment is becoming dynamic rather than static. And in SCLC brain management, MAVERICK asks whether better imaging may allow clinicians to safely use less treatment, not more.
This is an important distinction. Progress in thoracic oncology is increasingly defined not by therapeutic escalation alone, but by better selection, better sequencing, earlier molecular identification, and more precise decisions about who actually needs each component of treatment.
What to Watch as the WCLC Data Mature
The major late-breaking presentations over the next several days will determine how much of this emerging landscape becomes practice-changing.
For the SCLC trials, overall survival magnitude, toxicity, and the relative place of ADCs versus DLL3-directed T-cell engagement will be decisive. For EGFR exon 20 insertion disease, the key issue will increasingly be comparative first-line sequencing rather than whether the mutation is actionable.
For DESTINY-Lung04, the central question is whether the PFS advantage is sufficiently large, and the ILD and overall toxicity profile sufficiently manageable, to justify first-line T-DXd ahead of chemoimmunotherapy and competing HER2 TKIs. For ADAURA, durability years beyond completion of osimertinib will help define what adjuvant targeted therapy is actually accomplishing.
And for early-stage molecular therapy, NAUTIKA1 and related studies are beginning to test whether the biology that transformed metastatic NSCLC should also determine treatment before the tumor reaches the operating room.
The Bottom Line
WCLC 2026 arrives at a point when lung cancer treatment is moving beyond the simple division between chemotherapy, immunotherapy, and targeted therapy. The new model is increasingly stage-specific, mutation-specific, time-specific, and dynamically reassessed.
Small cell lung cancer, long one of the least therapeutically differentiated solid tumors, is gaining DLL3-directed T-cell engagers and B7-H3 ADCs. EGFR exon 20, HER2, ROS1, ALK, and KRAS-directed therapies are moving earlier in NSCLC. Perioperative treatment is becoming molecularly stratified. Even long-standing practices such as prophylactic cranial irradiation are being reevaluated against modern imaging.
As WCLC 2026 opens in Seoul, the most consequential question is therefore not simply which trial is positive. It is how these datasets will redraw the treatment sequence, from diagnosis and surgery through first-line therapy, maintenance, resistance, and relapse.
That may ultimately be the defining story of WCLC26.
